Q BioMed (QBIO) 10-Q2020 Q2 Quarterly report

Filed: 15 Jul 20, 4:53pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accessing, accomplishing, aging, allocate, arrive, attributable, BCF, biotech, Black, book, broadly, chemical, CLIA, command, composition, compound, constitute, core, corporate, cost, credit, dataset, deemed, delisting, deliver, delivered, depository, detection, device, discovered, discovery, dissolution, doctor, dollar, economic, eligible, expedient, extent, falling, feasible, floor, found, GDF, goal, gratifying, higher, inevitable, innovating, intravenously, involuntary, IVD, leaf, maintained, Medicaid, met, metric, Nasdaq, negative, Nightshade, ophthalmology, outreach, passage, penalty, perfect, pervasive, plant, potency, preliminary, Prescribing, primarily, prioritize, projected, proposal, proud, publicly, quickly, quotation, raw, real, registered, relevant, replica, resale, restriction, restructuring, robust, Safety, shareholder, showed, specialty, stockpile, structure, submission, suspended, suspension, thereon, threatened, title, today, transportation, undervalued, urgent, vitro, volume, voluntary, vote, Voting, website, wholesale, winding, writing, young

Removed: acquire, actively, Adding, aid, aim, ameliorate, amended, amendment, begin, Biotechnology, BNI, called, Canada, Canal, catalyst, cell, combination, commercialize, comparison, comprise, continued, contracting, County, court, damage, define, demonstrate, demonstrated, deserved, diagnosed, differential, Differentiation, dose, dosing, excellence, excited, exclusive, exemption, expectancy, expensive, expiring, expression, Factor, filing, finalizing, fluid, forward, generated, generic, group, hard, improved, infrastructure, insight, Institute, integrated, invoicing, IP, kit, label, landscape, lead, likelihood, manufacture, March, marker, mechanism, medical, medicine, mentioned, Metastron, MetastronTM, monitoring, national, natural, network, niche, notified, nuclear, Ontario, ophthalmic, optimization, order, parallel, performed, pharma, pharmacovigilance, physician, platform, precision, preclinical, protection, qualified, realize, recent, return, royalty, Schlemm, securing, seek, settlement, simple, sooner, step, study, subgroup, Supreme, target, targeted, tasked, test, tested, therapy, Uttroside, valuable, vessel, vivo, worked, York

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

QBIO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Q BioMed Inc. (the “Company”) for the quarterly period ended May 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Denis Corin, Chief Executive Officer (Principal Executive Officer and Acting Principal Financial and Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Dated: July 15, 2020
	/s/ Denis Corin
	Denis Corin
	Chief Executive Officer (Principal Executive Officer and Acting Principal Financial and Accounting Officer)